Results 11 to 20 of about 89,117 (340)

Bisphosphonate conjugation for bone specific drug targeting

Bone Reports, 2018
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone ...
Kristen B. Farrell, Alexander Karpeisky, Douglas H. Thamm, Shawn Zinnen   +3 more
doaj   +2 more sources

Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study [PDF]

PLoS ONE, 2018
Objective: Osteoporotic fragility fractures, that are common in men and women, signal increased risk of future fractures and of premature mortality. Less than one-third of postmenopausal women and fewer men are prescribed active treatments to reduce ...
Bliuc, Dana, Center, Jacqueline R, Dinant, Geert-Jan, Eisman, John A, Geusens, Piet P, McLellan, Alastair R, Tran, Thach, van den Bergh, Joop P, van Geel, Tineke A   +8 more
core   +5 more sources

Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.

JAMA Internal Medicine, 2021
Importance The clinical decision to initiate bisphosphonate therapy for the treatment of osteoporosis requires balancing shorter-term harms and burdens (eg, gastroesophageal irritation or severe musculoskeletal pain) with longer-term benefits in reducing
W. Deardorff, I. Cenzer, Brian Nguyen, Sei J. Lee   +3 more
semanticscholar   +1 more source

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

International Journal of Molecular Sciences, 2021
Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital
Zintle Mbese, B. Aderibigbe
semanticscholar   +1 more source

Carpal tunnel syndrome associated with oral bisphosphonates. A population-based cohort study [PDF]

, 2015
© 2016 Carvajal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Arias, LHM, Carvajal, A, Cornelius, VR, Escudero, A, Fierro, I, Molokhia, M, Sauzet, O, Sáinz, M   +7 more
core   +1 more source

Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. [PDF]

, 2013
Osteoarthritis (OA) is the most common form of arthritis worldwide. Pain and reduced function are the main symptoms in this prevalent disease. There are currently no treatments for OA that modify disease progression; therefore analgesic drugs and joint ...
AD Beswick, Alison J. Davis, AM Lievense, Caroline B. Hing, CO Bingham, D Moher, DA Walsh, DA Walsh, DJ Hunter, E Yusuf, G Saviola, GA Rodan, IK Haugen, JC Buckland-Wright, KA Reilly, LD Carbone, LL Laslett, M Jokar, M Moreau, M Rossini, M Sato, M van Tulder, MC Jensen, N Bellamy, N Sofat, Nidhi Sofat, Sam Eldabe, T Fujita, T Fujita, T Fujita, T Fujita, T Kawasaki, T Nishii, T Yoneda, TD Spector, TO Smith, Toby O. Smith, UA Liberman   +37 more
core   +5 more sources

Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model

BMC Musculoskeletal Disorders, 2017
Background Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion.
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek   +5 more
doaj   +1 more source

Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?

Drugs in Context, 2020
Background: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term ...
Louise Statham, Sharon Abdy, Terry J Aspray   +2 more
doaj   +1 more source

Biological evaluations of novel 2,3,3-Trisphosphonate in osteoclastic and osteoblastic activities [PDF]

, 2017
Bisphosphonates (BPs) are the first line treatment for many bone diseases including hypercalcimia associated with bone malignancies. In this paper, we introduce a new analogue of bisphosphonate called the 2,3,3-Trisphosphonate (2,3,3-TriPP) that was ...
Boccaccini, Aldo R., Cheong, Yuen Ki, Detsch, Rainer, Huang, Mei, Ren, Guogang   +4 more
core   +3 more sources

Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients

Frontiers in Pharmacology, 2018
Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years.
Sung-mok Jung, Sujeong Han, Hye-Young Kwon   +2 more
doaj   +1 more source